Search research articles
Contact Us
Filters
Showing results (21-30 of 56) with videos related to
Page
of 6
Sort By:
Ebiomedicine
|
May 28, 2021
Quantifying cell cycle-dependent drug sensitivities in cancer using a high throughput synchronisation and screening approach
Timothy I Johnson, Christopher J Minteer, Daniel Kottmann, et al.
Molecular Cancer Therapeutics
|
June 13, 2018
The ATR Inhibitor AZD6738 Synergizes with Gemcitabine <i>In Vitro</i> and <i>In Vivo</i> to Induce Pancreatic Ductal Adenocarcinoma Regression
Yann Wallez, Charles R Dunlop, Timothy Isaac Johnson, et al.
Blood
|
November 14, 2015
ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells
Marwan Kwok, Nicholas Davies, Angelo Agathanggelou, et al.
Cancers
|
August 26, 2023
Relevance of ATM Status in Driving Sensitivity to DNA Damage Response Inhibitors in Patient-Derived Xenograft Models
Ankur Karmokar, Rebecca Sargeant, Adina M Hughes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 25, 2010
Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts
Ursula Kortmann, Jessica N McAlpine, Hui Xue, et al.
Cancer Research
|
April 23, 2009
Poly(ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatin
Trevor Hay, James R Matthews, Lucie Pietzka, et al.
Cancer Research
|
January 26, 2022
ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib
Zena Wilson, Rajesh Odedra, Yann Wallez, et al.
Molecular Cancer Therapeutics
|
June 23, 2021
Radiopotentiation Profiling of Multiple Inhibitors of the DNA Damage Response for Early Clinical Development
Sonja J Gill, Paul W G Wijnhoven, Jacqueline H L Fok, et al.
Oncogene
|
May 24, 2020
Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells
Rebecca L Lloyd, Paul W G Wijnhoven, Antonio Ramos-Montoya, et al.
Journal of Medicinal Chemistry
|
June 4, 2016
Discovery of Novel 3-Quinoline Carboxamides as Potent, Selective, and Orally Bioavailable Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase
Sébastien L Degorce, Bernard Barlaam, Elaine Cadogan, et al.
Page
of 6
Search research articles
Search
Showing results (21-30 of 56) with videos related to
Sort By:
Page
of 6
Ebiomedicine
|
May 28, 2021
Quantifying cell cycle-dependent drug sensitivities in cancer using a high throughput synchronisation and screening approach
Timothy I Johnson, Christopher J Minteer, Daniel Kottmann, et al.
Molecular Cancer Therapeutics
|
June 13, 2018
The ATR Inhibitor AZD6738 Synergizes with Gemcitabine <i>In Vitro</i> and <i>In Vivo</i> to Induce Pancreatic Ductal Adenocarcinoma Regression
Yann Wallez, Charles R Dunlop, Timothy Isaac Johnson, et al.
Blood
|
November 14, 2015
ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells
Marwan Kwok, Nicholas Davies, Angelo Agathanggelou, et al.
Cancers
|
August 26, 2023
Relevance of ATM Status in Driving Sensitivity to DNA Damage Response Inhibitors in Patient-Derived Xenograft Models
Ankur Karmokar, Rebecca Sargeant, Adina M Hughes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 25, 2010
Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts
Ursula Kortmann, Jessica N McAlpine, Hui Xue, et al.
Cancer Research
|
April 23, 2009
Poly(ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatin
Trevor Hay, James R Matthews, Lucie Pietzka, et al.
Cancer Research
|
January 26, 2022
ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib
Zena Wilson, Rajesh Odedra, Yann Wallez, et al.
Molecular Cancer Therapeutics
|
June 23, 2021
Radiopotentiation Profiling of Multiple Inhibitors of the DNA Damage Response for Early Clinical Development
Sonja J Gill, Paul W G Wijnhoven, Jacqueline H L Fok, et al.
Oncogene
|
May 24, 2020
Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells
Rebecca L Lloyd, Paul W G Wijnhoven, Antonio Ramos-Montoya, et al.
Journal of Medicinal Chemistry
|
June 4, 2016
Discovery of Novel 3-Quinoline Carboxamides as Potent, Selective, and Orally Bioavailable Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase
Sébastien L Degorce, Bernard Barlaam, Elaine Cadogan, et al.
Page
of 6